The mutational profile of CRC tumors, including KRAS, NRAS, BRAF, PIK3CA, and AKT1 gene mutation and MSI status significantly influences the characteristics of the tumor microenvironment (TME) and directly impacts patient prognosis. This evidence concerns the gene KRAS and neoplasm.